A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
← catalyst calendarSponsored by Arcturus Therapeutics, Inc. (industry) · ARCT — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
9estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-04 | actual | When the study began enrolling |
| Primary completion | 2026-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- OTC Deficiency
- Ornithine Transcarbamylase Deficiency
- OTCD
Intervention
- Biological: ARCT-810
Primary outcome
what the primary-completion date above is the date OFIncidence, severity and dose-relationship of adverse events (AEs)
measured Day 85
Permalink · ARCT's whole pipeline · Catalyst calendar · Every registered study · What changed